
Researchers at the Mayo Clinic have found that mesenchymal stromal cells engineered with chimeric antigen receptors can enhance immunosuppression in the context of immune-related disorders.
Your AI-Trained Oncology Knowledge Connection!
Researchers at the Mayo Clinic have found that mesenchymal stromal cells engineered with chimeric antigen receptors can enhance immunosuppression in the context of immune-related disorders.
In a collaborative effort between 18 centers, researchers have developed a system that effectively stratifies children at the onset of acute graft versus host disease for risk of non-relapse mortality over 6 months.
Efficacy of post-transplant cyclophosphamide vs antithymocyte globulin remains a large discussion for patients with graft-vs-host disease.
ASTCT discusses Richter transformation and treatment options available for this population.
Researchers from MSKCC have explored the potential of personalized fludarabine dosing, based on population pharmacokinetics, to enhance the outcomes of CD19 CAR T-cell therapy in patients with relapsed/refractory aggressive B-cell non-Hodgkin lymphomas.
Researchers at the University of Birmingham in the UK have explored the dynamics of inflammatory biomarkers following allogeneic hematopoietic stem cell transplantation.
Dr. Mustafa Hyder spoke about the results from a phase 1/2 trial presented during the 2024 Tandem Meeting.
Amar H. Kelkar, MD, presented findings on the cost-effectiveness of transplantation therapy during the 2024 Tandem Meeting.
Rahul Banerjee, MD, FACP, highlights recent presented from the 2024 Tandem Meeting.
A phase 1 clinical trial has found the optimal dosing schedule with a tolerable safety profile of vibecotamab in patients with relapsed/refractory acute myeloid leukemia.
Overall, the findings highlight the potential of bispecific antibodies as salvage therapy post anti-CD19 CAR T cell treatment and challenges associated with allogeneic hematopoietic cell transplantation consolidation after bispecific antibodies therapy in patients with relapsed/refractory B-cell lymphomas .
A recent study published in Nucleus discussed the utility of T-cell replete cord blood transplant in patients with high-risk pediatric acute myeloid leukemia and myelodysplastic syndrome.
A recent study published in Nucleus highlighted the impact of graft-vs-host disease prophylaxis on cytomegalovirus reactivation.
Notch signaling acute gastrointestinal graft-vs-host disease was determined in a study analyzing mice and nonhuman primates.
ISB 1342 has shown improved safety and efficacy for patients with relapsed/refractory multiple myeloma.
Results from the phase 3 COG ALL1331 trial found the use of blinatumomab for pediatric patients with B-cell acute lymphoblastic leukemia improved efficacy.
The difference in utilizing cytomegalovirus reactivation outcomes while on posttransplantation cyclophosphamide vs other graft-vs-hose disease agents has led to a better understanding in long-term disease and reinfection rates.
A recent study has found that novel graft-versus-leukemia has minor histocompatibility antigens and was all validated.
Pediatric patients with acute lymphoblastic leukemia and have KMT2A rearrangements were evaluated in a recent study published in the British Journal of Haematology.
A study regarding next-generation sequencing evaluated minimal residual disease in patients with acute myeloid leukemia.
Rates of relapse and worse survival were associated with persistent FLT3-ITD or NPM1 variants prior to allogeneic hematopoietic stem cell transplant for patients with acute myeloid leukemia.
A recently published article highlights the use of CD4-positive/CD8-positive double-positive T cells as a predictive marker for graft-versus-host disease.
A recent study found for patients with graft-versus-host disease, a relationship was observed between CD38 expression which reduced survival and had a higher transplant-related mortality.
Jun J. Yang, PhD, reviews the use of ex vivo drug sensitivity profiles and in vivo early treatment response for patients with acute lymphoblastic leukemia.
Recent research found that the disialoganglioside 2–directed bispecific trifunctional antibody has 2 binding sites which allows for a mitigated T-cell anti-tumor response.
Alex Kradhim reviews how graft-versus-host disease can be maintained by tissue resident TCF-1+ T cells.
Alison Gulbis, PharmD, BCOP, discusses her experience of being a woman in the bone marrow transplant and cellular therapy field.
Rahul Banerjee, MD, FACP, discusses a recent presentation from the Tandem meeting regarding BCMA CAR T-cell therapy in patients with multiple myeloma.
Rahul Banerjee, MD, FACP, recounts the recent Tandem meeting by highlighting an interesting study involving cell phones and cell therapies.
Eleanor Mayfield, ELS, reviews the role of bispecific antibodies in hematologic malignancies.